8-K
0001831096false00018310962022-05-052022-05-05

 

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 5, 2022

 

Great Elm Group, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39832

85-3622015

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

800 South Street, Suite 230, Waltham, MA

 

02453

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 375-3006

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.001 per share

GEG

The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 


 

Item 2.02 Results of Operations and Financial Condition.

 

On May 5, 2022, Great Elm Group, Inc. issued the press release furnished as exhibit 99.1 to this report.

 

The foregoing information (including the exhibit hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibits are furnished with this report but shall not be deemed filed:

 

 

 

Exhibit

Number

 

Description

99.1

 

Press release, dated May 5, 2022.

104

 

The cover page from this current Report on Form 8-K, formatted as inline XBRL.

 

 


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

GREAT ELM GROUP, INC.

 

 

 

 

Date: May 5, 2022

 

/s/ Brent J. Pearson

 

 

By: Brent J. Pearson

 

 

Title: Chief Financial Officer

 

 


 

Great Elm Group Reports FISCAL 2022 THIRD QUARTER

financial resulTs

 

Company to Host Conference Call at 9:00 a.m. ET on May 6, 2022

 

WALTHAM, Mass., May 5, 2022 -- Great Elm Group, Inc. (“we,” “us,” “our,” “GEG,” or “Great Elm”), (NASDAQ: GEG), a diversified holding company, today announced financial results for its fiscal third quarter ended March 31, 2022.

 

Acquisition of Monomoy REIT Management Agreements for $10 million

Transformative transaction for GEG’s Investment Management Business detailed in a separate press release issued today
Furthers GEG’s Strategy of Adding a Long-Duration Capital Vehicle More Than Doubling AUM and Leveraging GEG’s Resources and Tax Attributes
Transaction Contemplates Growth Investment into Monomoy REIT of up to $30 Million
Acquisition was Unanimously Approved by GEG’s disinterested Directors and special committee

 

Filed S-1 Registration Statement for a Senior Unsecured Note offering

 

Fiscal 2022 Third Quarter Operating and Financial Highlights

(All comparisons versus the prior-year period unless otherwise noted)

 

Consolidated:

Consolidated revenue for the third quarter was $16.6 million, compared to $13.8 million.
Consolidated net loss from continuing operations for the third quarter was $6.1 million, compared to net loss from continuing operations of $2.8 million.
Consolidated Adjusted EBITDA for the third quarter was $1.0 million, compared to $2.2 million.
As of June 30, 2021, we had approximately $952 million of net operating loss (NOL) carryforwards for federal income tax purposes.

 

Investment Management (IM):

IM grew total revenue for the third quarter by 35.7% to $1.0 million, compared to $0.7 million.
IM net loss for the third quarter was $4.0 million, compared to a net loss of $0.7 million.
IM recognized Adjusted EBITDA of ($0.4) million for the third quarter, compared to approximately breakeven for the prior-year period.

 

Operating Companies:

Durable Medical Equipment (DME) grew total revenue for the third quarter by 19.2% to $15.6 million, compared to $13.1 million, driven by strong resupply sales despite challenging pandemic-related conditions.
DME net loss for the third quarter was $6.6 million, compared to a net loss of $5.1 million. These losses include $5.6 million and $4.8 million, respectively, in intercompany charges related to the valuation of an embedded derivative that eliminates in consolidation.
DME Adjusted EBITDA for the third quarter was $2.5 million, compared to $3.4 million. Exclusive of CARES Act stimulus received in the prior-year period, this represents an improvement of $1.4 million.
DME total revenue, net income and Adjusted EBITDA for the trailing 12 month period ended March 31, 2022 were $62.3 million, $2.3 million and $14.6 million, respectively, compared to $56.2 million, ($5.6) million and $15.0 million.

 

-1-


Management Commentary

 

Peter A. Reed, Chief Executive Officer, stated, “We have taken steps to execute on our strategy of growing the management of long duration capital vehicles. Today’s announcement of the Monomoy transaction exemplifies this strategy. In addition, we have taken steps to grow GECC and its specialty finance platform, including the acquisition of Sterling Commercial Credit in the quarter. Our financial results for the fiscal third quarter of 2022 reinforced the benefits of our unique and diversified business model, spanning long-term investments in high-quality, growing operating companies in addition to our differentiated investment management platform. Our investment in DME continues to perform well despite challenging supply chain conditions.”

 

Alignment of Interest

A distinct attribute of Great Elm is the particularly strong alignment of interest among shareholders and the employees, directors, and other insiders of Great Elm. As of March 31, 2022, Great Elm’s employees and directors (including funds under their management) collectively own or manage approximately 30% of GEG’s total outstanding shares.

 

Financial Review

 

Discussion of Financial Results by Segment for the Fiscal Quarter ended March 31, 2022

 

Great Elm is a holding company with two operating segments: Operating Companies and Investment Management, with General Corporate representing unallocated costs and activity to arrive at consolidated operations.

 

Investment Management

 

During the three months ended March 31, 2022, IM reported total revenue of $1.0 million, compared to $0.7 million during the same period in the prior year. Revenue for the quarter was higher due to an increase in the average assets on which such fees are calculated through growth of GECC and our private fund GESOF, which was launched in February 2021.

 

During the three months ended March 31, 2022, IM recognized a net loss of $4.0 million, compared to a net loss of $0.7 million during the same period in the prior year. The net loss increased primarily due to higher unrealized losses on our investment in GECC common shares during the period. We mark-to-market our investment in GECC and underlying investments of consolidated funds by reference to the closing price of related investments on Nasdaq or other exchanges, as applicable, as of each period end.

 

During the three months ended March 31, 2022, IM recognized Adjusted EBITDA of ($0.4) million compared to approximately breakeven for the same period in the prior year. Increased revenue was more than offset by higher selling, general and administrative expenses due to an increase in allocated payroll costs, bonus accruals and consulting fees.

 

Operating Companies

 

During the three months ended March 31, 2022, DME reported $15.6 million in total revenue, compared to $13.1 million during the same period in the prior year. The increase in revenue was primarily attributable to contributions from the previously acquisitions of AMPM in March 2021 and of MedOne in August 2021. Revenue continues to be impacted by supply chain issues, though our DME business maintains a large backlog of patients seeking PAP treatments.

 

-2-


During the three months ended March 31, 2022, DME recognized a net loss of $6.6 million, compared to net loss of $5.1 million for the same period in the prior year. These losses include charges of $5.6 million and $4.8 million, respectively, related to changes in value of an embedded derivative on an intercompany instrument held by the Corporate segment, which eliminate in consolidation. Moreover, year-over-year comparisons were impacted by meaningful Employee Retention Tax Credits in the prior period as the prior period includes $2.3 million in benefits received under the CARES Act. Excluding these credits, segment profitability significantly improved versus the prior-year quarter.

 

Normalized for these items, the remaining improvement of $1.6 million in net loss compared to the same period in the prior year is attributed largely due to revenue growth combined with ongoing expense management.

 

During the three months ended March 31, 2022, DME Adjusted EBITDA was $2.5 million, compared to $3.4 million in the prior-year period. As noted, the prior period includes $2.3 million in benefits received under the CARES Act, whereas no such benefit was received in the current period.

 

General Corporate

 

During the three months ended March 31, 2022, General Corporate recognized $0.2 million in revenue, approximately unchanged from the same period in the prior year. Revenue at General Corporate consists of management fees charged to subsidiaries and eliminate in consolidation.

 

During the three months ended March 31, 2022, General Corporate recognized net income from continuing operations of $4.5 million, compared to net income from continuing operations of $3.0 million during the same period in the prior year. $0.8 million of the year-over-year variance can be attributed to the change in value of an embedded derivative on an intercompany instrument issued by the Operating Companies segment, which eliminates in consolidation. The remaining improvement is primarily related to dividends and unrealized gains from our existing investment in Monomoy REIT

 

During the three months ended March 31, 2022, General Corporate recognized ($1.2) million of Adjusted EBITDA, approximately unchanged from Adjusted EBITDA of ($1.2) million during the same period in the prior year.

 

Fiscal 2022 Third Quarter Conference Call & Webcast Information

 

When: Friday, May 6, 2022, 9:00 a.m. Eastern Time (ET)

 

Call: All interested parties are invited to participate in the conference call by dialing +1 (888) 440-4537; international callers should dial +1 (646) 960-0669. Participants should enter the Conference ID 2595129 when asked.

 

Webcast: The conference call will be webcast simultaneously and can be accessed at the following link: https://events.q4inc.com/attendee/622762233. For a copy of the slide presentation accompanying the conference call, please visit: https://www.greatelmgroup.com/events-and-presentations.

 

About Great Elm Group, Inc.

 

Great Elm Group, Inc. (NASDAQ: GEG) is a publicly-traded holding company that is building a business across two operating verticals: Operating Companies and Investment Management. Great Elm Group, Inc.’s website can be found at www.greatelmgroup.com.

 

-3-


Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

 

Statements in this press release that are “forward-looking” statements, including statements regarding revenue, Adjusted EBITDA, expected growth, profitability, acquisition opportunities and outlook involve risks and uncertainties that may individually or collectively impact the matters described herein. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and represent Great Elm’s assumptions and expectations in light of currently available information. These statements involve risks, variables and uncertainties, and Great Elm’s actual performance results may differ from those projected, and any such differences may be material. For information on certain factors that could cause actual events or results to differ materially from Great Elm’s expectations, please see Great Elm’s filings with the SEC, including its most recent annual report on Form 10-K and subsequent reports on Forms 10-Q and 8-K. Additional information relating to Great Elm’s financial position and results of operations is also contained in Great Elm’s annual and quarterly reports filed with the SEC and available for download at its website www.greatelmgroup.com or at the SEC website www.sec.gov.

 

Please note that previously reported amounts below have been recast to 1) reflect the operations of our real estate business as discontinued operations; 2) reflect the full retrospective adoption of ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity; and 3) conform with current segment organization.

 

Non-GAAP Financial Measures

 

The SEC has adopted rules to regulate the use in filings with the SEC, and in public disclosures, of financial measures that are not in accordance with US GAAP, such as adjusted earnings before interest, taxes, depreciation and amortization (“Adjusted EBITDA”). Adjusted EBITDA is derived from methodologies other than in accordance with US GAAP. Great Elm believes that Adjusted EBITDA is an important measure for investors to use in evaluating Great Elm’s businesses. In addition, Great Elm’s management reviews Adjusted EBITDA as they evaluate acquisition opportunities.

 

Adjusted EBITDA has limitations as an analytical tool, and you should not consider it either in isolation from, or as a substitute for, analyzing Great Elm’s results as reported under US GAAP. Non-GAAP financial measures reported by Great Elm may not be comparable to similarly titled amounts reported by other companies.

 

Included in the financial tables below is a reconciliation of Adjusted EBITDA to the most directly comparable US GAAP financial measure, net income.

 

Investor Relations Contact:

Michael Kim / Garrett Edson

[email protected]

 

-4-


Great Elm Group, Inc.

Condensed Consolidated Balance Sheets (Unaudited)

Dollar amounts in thousands (except per share data)

ASSETS

 

March 31, 2022

 

 

June 30, 2021

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

22,746

 

 

$

24,382

 

Accounts receivable

 

 

7,684

 

 

 

6,518

 

Related party receivables

 

 

1,392

 

 

 

1,665

 

Investments, at fair value (cost $44,845 and $45,326, respectively)

 

 

19,160

 

 

 

24,044

 

Inventories

 

 

949

 

 

 

1,066

 

Prepaid and other current assets

 

 

1,007

 

 

 

3,791

 

Assets of Consolidated Funds

 

 

 

 

 

 

Investments, at fair value (cost $11,726 and $26,814, respectively)

 

 

11,340

 

 

 

26,490

 

Prepaid expenses and other assets

 

 

2,708

 

 

 

578

 

Total current assets

 

 

65,586

 

 

 

88,534

 

Property and equipment, net

 

 

613

 

 

 

981

 

Equipment held for rental, net

 

 

6,810

 

 

 

7,391

 

Identifiable intangible assets, net

 

 

7,733

 

 

 

8,928

 

Goodwill

 

 

52,463

 

 

 

50,536

 

Right of use assets

 

 

4,024

 

 

 

5,241

 

Other assets

 

 

236

 

 

 

258

 

Total assets

 

$

137,465

 

 

$

161,869

 

LIABILITIES, NON-CONTROLLING INTEREST AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

5,635

 

 

$

5,521

 

Accrued expenses and other liabilities

 

 

6,044

 

 

 

6,955

 

Deferred revenue

 

 

1,420

 

 

 

4,438

 

Current portion of lease liabilities

 

 

1,663

 

 

 

1,920

 

Current portion of capitalized equipment financing

 

 

2,711

 

 

 

1,974

 

Liabilities of Consolidated Funds- accrued expenses and other

 

 

93

 

 

 

12,197

 

Total current liabilities

 

 

17,566

 

 

 

33,005

 

Lease liabilities, net of current portion

 

 

2,587

 

 

 

3,596

 

Convertible notes (face value $35,205 and $34,346, respectively, including $16,637 and $16,231, respectively, held by related parties)

 

 

34,278

 

 

 

33,333

 

Equipment financing debt, net of current portion

 

 

-

 

 

 

67

 

Redeemable preferred stock of subsidiaries (held by related parties, face value $37,018)

 

 

35,694

 

 

 

35,529

 

Other liabilities

 

 

360

 

 

 

915

 

Total liabilities

 

 

90,485

 

 

 

106,445

 

Commitments and Contingencies (Note 18)

 

 

 

 

 

 

Contingently redeemable non-controlling interest

 

 

2,262

 

 

 

2,639

 

Stockholders' equity

 

 

 

 

 

 

Preferred stock, $0.001 par value; 5,000,000 authorized and zero outstanding

 

 

-

 

 

 

-

 

Common stock, $0.001 par value; 350,000,000 shares authorized and 27,464,767 shares issued and 26,963,203 outstanding at March 31, 2022; and 26,613,913 shares issued and 25,948,100 outstanding at June 30, 2021

 

 

27

 

 

 

26

 

Additional paid-in-capital

 

 

3,309,704

 

 

 

3,307,613

 

Accumulated deficit

 

 

(3,274,750

)

 

 

(3,264,403

)

Total Great Elm Group, Inc. stockholders' equity

 

 

34,981

 

 

 

43,236

 

Non-controlling interests

 

 

9,737

 

 

 

9,549

 

Total stockholders' equity

 

 

44,718

 

 

 

52,785

 

Total liabilities, non-controlling interest and stockholders' equity

 

$

137,465

 

 

$

161,869

 

 

 

 

-5-


Great Elm Group, Inc.

Condensed Consolidated Statements of Operations (Unaudited)

Dollar amounts in thousands (except per share data)

 

 

For the three months ended March 31,

 

 

For the nine months ended March 31,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Durable medical equipment sales and services revenue

 

$

10,359

 

 

$

8,606

 

 

$

30,712

 

 

$

27,363

 

Durable medical equipment rental income

 

 

5,275

 

 

 

4,511

 

 

 

16,205

 

 

 

14,907

 

Investment management revenues

 

 

988

 

 

 

728

 

 

 

2,992

 

 

 

2,261

 

Total revenues

 

 

16,622

 

 

 

13,845

 

 

 

49,909

 

 

 

44,531

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating costs and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of durable medical equipment sold and services

 

 

4,362

 

 

 

3,806

 

 

 

12,731

 

 

 

12,716

 

Cost of durable medical equipment rentals(1)

 

 

1,708

 

 

 

1,657

 

 

 

5,292

 

 

 

5,193

 

Durable medical equipment other operating expenses(2)

 

 

8,758

 

 

 

6,084

 

 

 

23,551

 

 

 

21,834

 

Investment management expenses

 

 

1,592

 

 

 

904

 

 

 

4,748

 

 

 

2,546

 

Depreciation and amortization

 

 

517

 

 

 

618

 

 

 

1,631

 

 

 

1,799

 

Selling, general and administrative(3)

 

 

1,582

 

 

 

1,854

 

 

 

4,620

 

 

 

4,582

 

Expenses of Consolidated Funds

 

 

42

 

 

 

19

 

 

 

139

 

 

 

27

 

Total operating costs and expenses

 

 

18,561

 

 

 

14,942

 

 

 

52,712

 

 

 

48,697

 

Operating loss

 

 

(1,939

)

 

 

(1,097

)

 

 

(2,803

)

 

 

(4,166

)

Dividends and interest income

 

 

642

 

 

 

554

 

 

 

1,939

 

 

 

2,408

 

Net realized and unrealized (loss) gain on investments

 

 

(3,220

)

 

 

(1,112

)

 

 

(5,055

)

 

 

(454

)

Net realized and unrealized gain (loss) on investments of Consolidated Funds

 

 

(284

)

 

 

155

 

 

 

(279

)

 

 

221

 

Interest expense

 

 

(1,354

)

 

 

(1,361

)

 

 

(4,078

)

 

 

(3,607

)

Loss on extinguishment of debt

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(1,866

)

Other income, net

 

 

-

 

 

 

-

 

 

 

2

 

 

 

30

 

Loss from continuing operations, before income taxes

 

 

(6,155

)

 

 

(2,861

)

 

 

(10,274

)

 

 

(7,434

)

Income tax benefit (expense)

 

 

20

 

 

 

43

 

 

 

86

 

 

 

(6

)

Loss from continuing operations

 

 

(6,135

)

 

 

(2,818

)

 

 

(10,188

)

 

 

(7,440

)

Discontinued operations:

 

 

 

 

 

 

 

 

 

 

 

 

Income from discontinued operations, net of tax

 

 

-

 

 

 

73

 

 

 

-

 

 

 

211

 

Net loss

 

$

(6,135

)

 

$

(2,745

)

 

$

(10,188

)

 

$

(7,229

)

Less: net income (loss) attributable to non-controlling interest, continuing operations

 

 

(226

)

 

 

(173

)

 

 

159

 

 

 

(907

)

Less: net income attributable to non-controlling interest, discontinued operations

 

 

-

 

 

 

15

 

 

 

-

 

 

 

45

 

Net loss attributable to Great Elm Group, Inc.

 

$

(5,909

)

 

$

(2,587

)

 

$

(10,347

)

 

$

(6,367

)

Basic and diluted income (loss) per share from:

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

(0.22

)

 

$

(0.10

)

 

$

(0.38

)

 

$

(0.25

)

Discontinued operations

 

 

-

 

 

 

0.00

 

 

 

-

 

 

 

(0.00

)

Net loss

 

$

(0.22

)

 

$

(0.10

)

 

$

(0.38

)

 

$

(0.25

)

Weighted average shares outstanding

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

26,842

 

 

 

25,757

 

 

 

26,963

 

 

 

25,669

 

Diluted

 

 

26,842

 

 

 

25,757

 

 

 

26,963

 

 

 

25,669

 

(1) Includes depreciation expense of:

 

 

1,575

 

 

 

1,478

 

 

 

4,860

 

 

 

4,683

 

(2) Net of CARES Act Stimulus of:

 

 

-

 

 

 

2,275

 

 

 

2,321

 

 

 

2,275

 

(3) Net of CARES Act Stimulus of:

 

 

-

 

 

 

-

 

 

 

84

 

 

 

-

 

 

 

 

 

 

 

 

-6-


Great Elm Group, Inc.

Reconciliation from EBITDA to Adjusted EBITDA - Quarterly

Dollar amounts in thousands (except per share data)

 

 

 

For the three months ended March 31, 2022

 

$ in thousands

 

Durable Medical Equipment

 

 

Investment Management

 

 

General Corporate

 

 

Consolidated

 

EBITDA:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) from continuing operations - GAAP

 

$

(6,620

)

 

$

(3,981

)

 

$

4,466

 

 

$

(6,135

)

Interest expense

 

 

1,269

 

 

 

24

 

 

 

1,263

 

 

 

2,556

 

Interest income from preferred stock

 

 

-

 

 

 

-

 

 

 

(1,202

)

 

 

(1,202

)

Depreciation & amortization

 

 

2,003

 

 

 

89

 

 

 

-

 

 

 

2,092

 

Tax expense (benefit)

 

 

-

 

 

 

-

 

 

 

(20

)

 

 

(20

)

EBITDA

 

 

(3,348

)

 

 

(3,868

)

 

 

4,507

 

 

 

(2,709

)

Adjusted EBITDA

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-cash compensation

 

 

-

 

 

 

262

 

 

 

316

 

 

 

578

 

Change in contingent consideration

 

 

68

 

 

 

-

 

 

 

-

 

 

 

68

 

Dividend income

 

 

-

 

 

 

(548

)

 

 

(96

)

 

 

(644

)

(Gains) / losses on investments

 

 

-

 

 

 

3,770

 

 

 

(266

)

 

 

3,504

 

Other (income) expense

 

 

5,612

 

 

 

-

 

 

 

(5,612

)

 

 

-

 

Transaction and integration related costs (2)

 

 

63

 

 

 

-

 

 

 

92

 

 

 

155

 

DME management and monitoring fees

 

 

117

 

 

 

-

 

 

 

(117

)

 

 

-

 

Adjusted EBITDA

 

$

2,512

 

 

$

(384

)

 

$

(1,176

)

 

$

952

 

 

 

 

For the three months ended March 31, 2021

 

$ in thousands

 

Durable Medical Equipment

 

 

Investment Management (1)

 

 

General Corporate (1)

 

 

Consolidated

 

EBITDA:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) from continuing operations - GAAP

 

$

(5,059

)

 

$

(732

)

 

$

2,973

 

 

$

(2,818

)

Interest expense

 

 

1,280

 

 

 

25

 

 

 

1,287

 

 

 

2,592

 

Interest income from preferred stock

 

 

-

 

 

 

-

 

 

 

(1,168

)

 

 

(1,168

)

Depreciation & amortization

 

 

1,986

 

 

 

109

 

 

 

1

 

 

 

2,096

 

Tax expense (benefit)

 

 

-

 

 

 

-

 

 

 

(43

)

 

 

(43

)

EBITDA

 

 

(1,793

)

 

 

(598

)

 

 

3,050

 

 

 

659

 

Adjusted EBITDA

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-cash compensation

 

 

-

 

 

 

181

 

 

 

470

 

 

 

651

 

GECC dividend income

 

 

-

 

 

 

(554

)

 

 

-

 

 

 

(554

)

GECC unrealized (gains) / losses

 

 

-

 

 

 

984

 

 

 

-

 

 

 

984

 

Other (income) expense

 

 

4,795

 

 

 

-

 

 

 

(4,795

)

 

 

-

 

Transaction and integration related costs (2)

 

 

380

 

 

 

-

 

 

 

155

 

 

 

535

 

DME management and monitoring fees

 

 

46

 

 

 

-

 

 

 

(46

)

 

 

-

 

Adjusted EBITDA

 

$

3,428

 

 

$

13

 

 

$

(1,166

)

 

$

2,275

 

 

 

 

For the nine months ended March 31, 2022

 

$ in thousands

 

Durable Medical Equipment

 

 

Investment Management

 

 

General Corporate

 

 

Consolidated

 

EBITDA:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) from continuing operations - GAAP

 

$

(3,601

)

 

$

(6,752

)

 

$

165

 

 

$

(10,188

)

Interest expense

 

 

3,845

 

 

 

72

 

 

 

3,801

 

 

 

7,718

 

Interest income on preferred stock

 

 

-

 

 

 

-

 

 

 

(3,640

)

 

 

(3,640

)

Depreciation & amortization

 

 

6,185

 

 

 

306

 

 

 

1

 

 

 

6,492

 

Tax expense (benefit)

 

 

-

 

 

 

-

 

 

 

(86

)

 

 

(86

)

EBITDA

 

$

6,429

 

 

$

(6,374

)

 

$

241

 

 

$

296

 

Adjusted EBITDA

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-cash compensation

 

 

-

 

 

 

1,604

 

 

 

968

 

 

 

2,572

 

Change in contingent consideration

 

 

(380

)

 

 

-

 

 

 

-

 

 

 

(380

)

Dividend income

 

 

-

 

 

 

(1,651

)

 

 

(288

)

 

 

(1,939

)

(Gains) / Losses on investments

 

 

-

 

 

 

6,130

 

 

 

(796

)

 

 

5,334

 

Other (income) expense

 

 

3,468

 

 

 

-

 

 

 

(3,470

)

 

 

(2

)

Transaction and integration costs (2)

 

 

458

 

 

 

-

 

 

 

311

 

 

 

769

 

DME management and monitoring fees

 

 

307

 

 

 

-

 

 

 

(307

)

 

 

-

 

Adjusted EBITDA

 

$

10,282

 

 

$

(291

)

 

$

(3,341

)

 

$

6,650

 

 

-7-


 

 

For the nine months ended March 31, 2021

 

$ in thousands

 

Durable Medical Equipment

 

 

Investment Management (1)

 

 

General Corporate (1)

 

 

Consolidated

 

EBITDA:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) from continuing operations - GAAP

 

$

(8,395

)

 

$

1,415

 

 

$

(459

)

 

$

(7,439

)

Interest expense

 

 

2,676

 

 

 

76

 

 

 

2,086

 

 

 

4,838

 

Interest income on preferred stock

 

 

-

 

 

 

-

 

 

 

(1,168

)

 

 

(1,168

)

Depreciation & amortization

 

 

6,116

 

 

 

364

 

 

 

2

 

 

 

6,482

 

Tax expense (benefit)

 

 

-

 

 

 

-

 

 

 

6

 

 

 

6

 

EBITDA

 

 

397

 

 

 

1,855

 

 

 

467

 

 

 

2,718

 

Adjusted EBITDA

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-cash compensation

 

 

-

 

 

 

572

 

 

 

793

 

 

 

1,365

 

Dividend income

 

 

-

 

 

 

(2,400

)

 

 

-

 

 

 

(2,400

)

(Gains) / losses on investments

 

 

-

 

 

 

260

 

 

 

-

 

 

 

260

 

Other (income) expense

 

 

4,765

 

 

 

-

 

 

 

(4,795

)

 

 

(30

)

Transaction and integration related costs (2)

 

 

780

 

 

 

-

 

 

 

417

 

 

 

1,197

 

Extinguishment of debt

 

 

1,866

 

 

 

 

 

 

 

 

 

 

 

1,866

 

Location closure

 

 

54

 

 

 

-

 

 

 

-

 

 

 

54

 

DME management and monitoring fees

 

 

224

 

 

 

-

 

 

 

(182

)

 

 

42

 

Adjusted EBITDA

 

$

8,086

 

 

$

287

 

 

$

(3,300

)

 

$

5,072

 

 

(1)
Previously reported prior year amounts have been recast to reflect the full retrospective adoption of ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity; and to conform with current segment organization.
(2)
Transaction and integration related costs include costs to acquire and integrate acquired businesses.

 

 

 

-8-